Randomized Evaluation of Shenfu Injection to Reduce Myocardial Injury

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 326 participants.

Also called NCT04493840

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 326 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04493840
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04493840. Randomized; triple masking; primary purpose treatment. Start 2020-07-30 (actual); primary completion 2022-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Evaluation of Shenfu Injection to Reduce Myocardial Injury
Acronym
RESTORE
Intervention (Drug)
Shenfu Injection
Intervention (Drug)
5% Glucose Injection
Lead sponsor
Beijing Anzhen Hospital (class: other)

Record details

Record id
cardio:ct-nct04493840
Content hash
8f3212a2d54849a862286600113d7c4bfcf223d4c4c3d5ea38ac31e8d7dd47cd